Working Group 3: Automating release

WORKING GROUP 3
Automating release for autologous products

Topics covered: In absence of tailored solutions for automating QC and release, what are we doing with the technology that we've got? How can I use automation to limit variabilily? Looking at common assays across advanced therapies and what opportunities does automation hold for those? Fill and finish automation. The long-term direction of travel is to eliminate QC facilities - what is on the wishlist of solutions to make this a reality? 

Outcome: Publish a collection of recommendations for industrialising QC for autologous products in today's environment. En route to the goal of industrialising production of autologous therapeutics, what practical solutions are being implemented today?

Who should attend?
  • Autologous biotechs of all clinical stages, with a challenging release process, that are looking towards automation to limit variability, ideally with experience building custom solutions or repurposing existing technology to scale up
  • Engineering firms working with biotech on in-line analytics
  • CMOs
  • Vendors in this space¬†
PLEASE FILL OUT THE FORM BELOW TO APPLY FOR THIS WORKING GROUP